Allakos Inc.
9.60%
8,693,687
1564824
01671P100
Apr 14, 2025
Apr 17, 2025, 04:01 PM
Reporting Persons (8)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | Other | 9.60% | 8,693,687 | 0 | 8,693,687 |
| KEVIN TANG | Individual | 9.60% | 8,693,687 | 0 | 8,693,687 |
| TANG CAPITAL PARTNERS, LP | Partnership | 5.40% | 4,889,330 | 0 | 4,889,330 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 4.20% | 3,804,357 | 0 | 3,804,357 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.00% | 0 | 0 | 0 |
| CONCENTRA BIOSCIENCES, LLC | Other | 0.00% | 0 | 0 | 0 |
| CONCENTRA MERGER SUB III, INC | CO | 0.00% | 0 | 0 | 0 |
Disclosure Items (5)
Common Stock, par value $0.001 per share
Allakos Inc.
825 Industrial Road, San Carlos, CA, 94070
The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following: This Statement is voluntarily filed by TCM, a Delaware limited liability company that is the general partner of TCP and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; Tang Capital Partners III, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP III"); Tang Capital Partners IV, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP IV"); Concentra Biosciences, LLC, a Delaware limited liability company ("Concentra"); and Concentra Merger Sub III, Inc., a Delaware corporation that is a wholly owned subsidiary of Concentra ("Merger Sub III" and, collectively with TCM, Kevin Tang, TCP, TCPI, TCP III TCP IV and Concentra, the "Reporting Persons").
The address of TCM, Kevin Tang, TCP, TCPI, Concentra and Merger Sub III is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. Kevin Tang is the Chief Executive Officer of Concentra and Merger Sub III.
During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
See Item 2(a) above.
Item 6 of the Schedule D is amended by adding the following: The information set forth in Item 4 under the heading "Tender Offer" is incorporated herein by reference.
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on February 3, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 2: Schedule A: Transactions during the past 60 days (filed as Exhibit 2 of the 13D/A filed on April 3, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 3: Agreement and Plan of Merger, dated April 1, 2025, by and among Concentra Biosciences, LLC, Concentra Merger Sub III, Inc. and Allakos Inc. (filed as Exhibit 2.1 of the Issuer's Current Report filed on Form 8-K on April 2, 2025). Exhibit 4: Schedule TO (filed by Merger Sub III on April 15, 2025). Exhibit 5: Offer to Purchase, dated April 15, 2025 (filed as Exhibit (a)(1)(A) to the Schedule TO filed by Merger Sub III on April 15, 2025). Exhibit 6: Form of Letter of Transmittal (filed as Exhibit (a)(1)(B) to the Schedule TO filed by Merger Sub III on April 15, 2025. Exhibit 7: Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (filed as Exhibit (a)(1)(C) to the Schedule TO filed by Merger Sub III on April 15, 2025. Exhibit 8: Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (filed as Exhibit (a)(1)(D) to the Schedule TO filed by Merger Sub III on April 15, 2025. Exhibit 9: Mutual Confidentiality Agreement dated February 20, 2025 between Allakos and TCM (filed as Exhibit (d)(2) to the Schedule TO filed by Merger Sub III on April 15, 2025). Exhibit 10: Limited Guaranty, dated April 1, 2025 (filed as Exhibit (d)(3) to the Schedule TO filed by Merger Sub III on April 15, 2025). Exhibit 11: Joint Filing Agreement, dated April 17, 2025, by and among the Reporting Persons.